About The Zelarion Group
The Zelarion Group is the owner of the novel monoclonal antibody TCD601 (also known as siplizumab) as well as the pharmaceutical company ITBMED which is driving the development and clinical studies of TCD601. Specifically, TCD601 is being broadly developed for applications within transplantation and autoimmunity. Clinical Trials are being executed globally with a particular focus on the United States (US) and the European Union (EU) with an aim to submit applications for market authorization. To this effect, the group has secured regulatory incentives to increase the chances of market approval, such as Orphan Drug Designation both in the US and the EU. In addition, second generation treatments are being developed that can further broaden the use of the group’s immune modulating approach.